Chiauranib

DB16124InvestigationalSmall molecule

Chiauranib is under investigation in clinical trial NCT03974243 (Chiauranib in Combination With Chidamide in Patients With Relapsed/refractory Non-hodgkin's Lymphoma).

Mechanism: Pharmacologically active on Aurora kinase B and Vascular endothelial growth factor receptor
Curator reviewed
Formula / weight: C₂₇H₂₁N₃O₃ · 435.483 g/mol (avg)
Also known as: Ibcasertib
Code names: CS-2164

Resolves to

Compound

UNIIF40IRN5981CAS1256349-48-0

Structure

InChIKeyBRKWREZNORONDU-UHFFFAOYSA-NSMILESCOC1=CC=C2C(OC3=CC4=CC=CC(C(=O)NC5=CC=CC=C5N)=C4C=C3)=CC=NC2=C1

Targets

Q96GD4AURKB

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

17Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Chiauranib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account